Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Li-Fraumeni syndrome: a p53 family affair.

Iwakuma T, Lozano G, Flores ER.

Cell Cycle. 2005 Jul;4(7):865-7. Review.

PMID:
15917654
2.

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G.

Cell. 2004 Dec 17;119(6):861-72.

3.
4.

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T.

Cell. 2004 Dec 17;119(6):847-60.

5.

Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.

Piao J, Sakurai N, Iwamoto S, Nishioka J, Nakatani K, Komada Y, Mizutani S, Takagi M.

Mol Carcinog. 2013 Oct;52(10):770-6. doi: 10.1002/mc.21912.

PMID:
22495821
6.

Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members.

Lomax ME, Barnes DM, Hupp TR, Picksley SM, Camplejohn RS.

Oncogene. 1998 Aug 6;17(5):643-9.

7.

Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations.

Xu J, Qian J, Hu Y, Wang J, Zhou X, Chen H, Fang JY.

Sci Rep. 2014 Feb 27;4:4223. doi: 10.1038/srep04223.

8.

Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.

Malkin D, Chilton-MacNeill S, Meister LA, Sexsmith E, Diller L, Garcea RL.

Oncogene. 2001 Jul 27;20(33):4441-9.

9.
10.
11.

Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.

Adhikari AS, Iwakuma T.

Fukuoka Igaku Zasshi. 2009 Jun;100(6):217-28. Review.

PMID:
19670804
12.

Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.

Frebourg T, Kassel J, Lam KT, Gryka MA, Barbier N, Andersen TI, Børresen AL, Friend SH.

Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6413-7.

13.

p53 expression in three separate tumours from a patient with Li-Fraumeni's syndrome.

King P, Craft AW, Malcolm AJ.

J Clin Pathol. 1993 Jul;46(7):676-7.

14.

Divergent control of Cav-1 expression in non-cancerous Li-Fraumeni syndrome and human cancer cell lines.

Sherif ZA, Sultan AS.

Cancer Biol Ther. 2013 Jan;14(1):29-38. doi: 10.4161/cbt.22621.

15.

A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.

Plummer SJ, Santibáñez-Koref M, Kurosaki T, Liao S, Noble B, Fain PR, Anton-Culver H, Casey G.

Oncogene. 1994 Nov;9(11):3273-80.

PMID:
7936651
16.

Complex replication error causes p53 mutation in a Li-Fraumeni family.

Strauss EA, Hosler MR, Herzog P, Salhany K, Louie R, Felix CA.

Cancer Res. 1995 Aug 1;55(15):3237-41.

17.

Li-Fraumeni and Li-Fraumeni-like syndrome mutations in p53 are associated with exonic methylation and splicing regulatory elements.

Kouidou S, Malousi A, Maglaveras N.

Mol Carcinog. 2009 Oct;48(10):895-902. doi: 10.1002/mc.20537.

PMID:
19367569
18.

Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.

Kuperwasser C, Hurlbut GD, Kittrell FS, Dickinson ES, Laucirica R, Medina D, Naber SP, Jerry DJ.

Am J Pathol. 2000 Dec;157(6):2151-9.

19.

Multiple synchronous lung cancers and atypical adenomatous hyperplasia in Li-Fraumeni syndrome.

Nadav Y, Pastorino U, Nicholson AG.

Histopathology. 1998 Jul;33(1):52-4.

PMID:
9726049
20.

Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.

Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ, Varley JM.

Oncogene. 1998 Sep 3;17(9):1061-8.

Supplemental Content

Support Center